Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Syndax Pharmaceuticals (SNDX) Equity Ratio (2016 - 2025)

Syndax Pharmaceuticals has reported Equity Ratio over the past 11 years, most recently at 0.12 for Q4 2025.

  • Quarterly results put Equity Ratio at 0.12 for Q4 2025, down 69.31% from a year ago — trailing twelve months through Dec 2025 was 0.12 (down 69.31% YoY), and the annual figure for FY2025 was 0.12, down 69.31%.
  • Equity Ratio for Q4 2025 was 0.12 at Syndax Pharmaceuticals, down from 0.21 in the prior quarter.
  • Over the last five years, Equity Ratio for SNDX hit a ceiling of 0.95 in Q1 2023 and a floor of 0.12 in Q4 2025.
  • Median Equity Ratio over the past 5 years was 0.89 (2022), compared with a mean of 0.74.
  • Biggest five-year swings in Equity Ratio: soared 60.35% in 2021 and later crashed 75.69% in 2025.
  • Syndax Pharmaceuticals' Equity Ratio stood at 0.91 in 2021, then rose by 3.51% to 0.94 in 2022, then decreased by 3.81% to 0.9 in 2023, then plummeted by 56.04% to 0.4 in 2024, then crashed by 69.31% to 0.12 in 2025.
  • The last three reported values for Equity Ratio were 0.12 (Q4 2025), 0.21 (Q3 2025), and 0.26 (Q2 2025) per Business Quant data.